Workflow
深圳微芯生物科技股份有限公司前次募集资金使用情况的专项报告

Group 1 - The company raised a total of RMB 500 million through the issuance of 5 million convertible bonds, with a net amount of RMB 484.54 million after deducting issuance costs of RMB 15.46 million [2][3] - The funds were fully received on July 11, 2022, and verified by KPMG Huazhen [2] - As of March 31, 2025, the company reported no surplus in the use of the raised funds [13] Group 2 - The company adjusted its investment projects to meet market demand for Seglitazone, reallocating funds from the original CS12192 project to the Seglitazone production facilities [4] - The total actual investment in the projects may differ from the committed amounts, with details provided in the attached tables [5][14] - The company has utilized RMB 73.72 million of the raised funds to replace pre-invested self-raised funds for the investment projects [6] Group 3 - The company has engaged in cash management of temporarily idle funds, with a maximum of RMB 300 million allocated for safe and liquid investment products [9][10][11] - As of March 31, 2025, the company reported on the management of temporarily idle funds [12] Group 4 - The company will hold an online investor briefing on August 27, 2025, to discuss its half-year results and address investor questions [17][18] - The briefing will be conducted via the Shanghai Stock Exchange Roadshow Center, allowing for interactive communication with investors [18][19]